Although the precise function of sleep is unknown, decades of research strongly implicate that sleep has a vital role in central nervous system (CNS) restoration, memory consolidation, and affect regulation. Slow-wave sleep (SWS) and rapid eye movement (REM) sleep have been of significant interest to psychiatrists; SWS because of its putative role in CNS energy recuperation and cognitive function, and REM sleep because of its suggested involvement in memory, mood regulation, and possible emotional adaptation. With the advent of the polysomnogram, researchers are now beginning to understand some of the consequences of disrupted sleep and sleep deprivation in psychiatric disorders. The same neurochemistry that controls the sleep-wake cycle has also been implicated in the pathophysiology of numerous psychiatric disorders. Thus it is no surprise that several psychiatric disorders have prominent sleep symptoms. This review will summarize normal sleep architecture, and then examine sleep abnormalities and comorbid sleep disorders seen in schizophrenia, as well as anxiety, cognitive, and substance abuse disorders.
S leep is divided into 2 main types: REM sleep and NREM sleep. NREM sleep is further subdivided; Stages 1 and 2 are light stages of sleep (now referred to as N1 and N2), while Stages 3 and 4 are deeper stages (now referred to as N3), collectively referred to as SWS. SWS is important in CNS energy restoration and declarative memory (memory for facts and [or] events), 1, 2 which has significant consequences for psychiatric disorders with cognitive dysfunction. For example, SWS deficits are seen in schizophrenia 3 and Alzheimer disease. 4 REM sleep likely has a significant role in memory consolidation and affect regulation. The "mood regulatory function of dreaming" 5, p 261 hypothesis suggests that the function of the transition from SWS to REM sleep is to mitigate the affect of the previous waking experience. 5, 6 One model advanced by Walker 7 is that sleep modulates the emotional tone of memory. In what he called the "sleep to remember" and "sleep to forget" hypotheses, Walker 7 speculates that "emotional memories" are formed in a "milieu of high adrenergic [emotional] tone." p 190 Using some elegant experiments, Walker's data suggest that while sleep plays a role in enhancing declarative memory, sleep (especially REM sleep) may also play a role in stripping the emotional valence of a memory over time. For instance, after an emotionally traumatic event, with multiple iterations of sleep, the emotional tone of the memory diminishes, while the factual memory of the events remains intact. In this hypothesis, several psychiatric disorders may be impacted if this emotional adaptation function of REM sleep is compromised. PTSD would be a classic example of a malfunction of this putative emotional adaptation process, where the emotional content of a previous traumatic event persists. REM sleep abnormalities are seen in numerous psychiatric disorders, some of which will be examined below.
Insomnia, defined as difficulty initiating or maintaining sleep resulting in daytime consequences, is common among psychiatric disorders. Several potential comorbid sleep disorders, including OSA, RLS, PLMD, and RBD may modulate psychiatric symptom expression. This review will examine sleep abnormalities and comorbid sleep disorders in schizophrenia, anxiety, cognitive, and substance abuse disorders.
Sleep and Schizophrenia
Insomnia in schizophrenia is common, having been objectively validated in 2 large meta-analyses. 8, 9 Severe insomnia can be a prodromal symptom to psychotic decompensation and (or) relapse to psychosis following antipsychotic discontinuation. 10 The sleep abnormality most consistently found in patients with schizophrenia is a short REM latency, defined as the time from sleep onset to the first REM period. 3, 11 This short REM latency is likely secondary to SWS deficits, which may passively reduce REM latency. 12 SWS deficits have been seen frequently in schizophrenia, 13 even in first-episode neuroleptic-naive patients. 3 SWS is believed to provide a cortical restorative recovery from wakefulness 1, 14 and to enhance declarative memory consolidation. 15 Therefore, SWS deficiency in schizophrenia may play a significant role in cognitive and negative symptoms. 16 Both short REM latency 17 and SWS deficits 18, 19 are positively correlated with negative symptoms and cognitive dysfunction. Additional studies illustrate a relation between SWS deficits and CNS structural abnormalities seen in schizophrenia, including increased ventricular volume. 20, 21 However, whether this is a cause or an effect of the underlying disorder is unknown.
Shortened REM latency is also seen in narcolepsy and several psychiatric disorders, 22 limiting the use of this finding. In severe narcolepsy, the hypnagogic and hypnopompic hallucinations, believed to be REM intrusion phenomena of dreaming into wakefulness, can be misdiagnosed as psychotic symptoms of schizophrenia. 23, 24 This has significant treatment implications, as stimulant therapy may ameliorate hypnagogic and hypnopompic hallucinations 25 but would exacerbate schizophrenia. Although challenging, narcoleptic hallucinations can be distinguished from schizophrenic hallucinations by their holistic presentation. Narcoleptic hallucinations are often characterized by a multimodal perceptual experience including visual, auditory, and tactile elements, whereas in schizophrenia, hallucinations are often unimodal and frequently auditory. 26 Additionally, narcoleptic hallucinations are not accompanied by delusional symptoms or loss of touch with reality. 26 W La Revue canadienne de psychiatrie, vol 55, no 7, juillet 2010 404
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Antipsychotics and Sleep
Antipsychotics are currently the mainstay of schizophrenia treatment. 27 First-generation (typical) antipsychotics are primarily dopaminergic antagonists, with antihistaminergic and anticholinergic effects. Second-generation (atypical) antipsychotics have the added effect of blocking serotonergic receptors and are associated with improvement of negative and cognitive symptoms. 28 The central H1 (histaminergic one) antihistaminergic effects of antipsychotics have significant sedating properties, which may be beneficial for patients with schizophrenia and insomnia. Olanzapine is the most sedating of the atypical antipsychotics. 29 However, excessive daytime sedation can facilitate a reversal of the sleep-wake cycle, as daytime naps may enhance nighttime wakefulness, paradoxically exacerbating insomnia. 3 0 Another antihistaminergic effect is increased appetite and weight gain, which can increase the risk of developing OSA. 31 OSA may often go unrecognized in these patients and can contribute to several problems including aggressive behaviours. Anecdotal reports of severely aggressive patients with schizophrenia and unrecognized OSA have shown that, once treated with CPAP, aggressive tendencies diminished dramatically. 32 Dopaminergic antagonism also has significant sleep effects. Dopamine antagonism has been linked to exacerbation of RLS and PLMs, which can fragment sleep and contribute to daytime sleepiness. This has been demonstrated in case reports for olanzapine, 33 risperidone, 34 and quetiapine. 35 Serotonergic actions also play a role in sleep architecture changes. 5-HT 1A agonist effects suppress REM sleep. 30 For instance, ziprasidone has strong 5-HT 1A agonism effects and significantly suppresses REM sleep. 30 Increased SWS is correlated significantly with 5-HT 2 antagonism. Olanzapine 36 and risperidone 37 have high 5-HT 2 antagonism and are reported to increase SWS the most among antipsychotics. Ziprasidone also increases SWS, but quetiapine does not increase SWS in healthy patients, likely because of less 5-HT 2 antagonism. 30 Paliperidone has not been shown to increase SWS. 38 For a summary of these effects, see Table 1 .
Interpreting these findings can be challenging because these effects are studied in different populations, from control subjects to patients with different psychiatric conditions, leading to conflicting findings. Additionally, it is unclear that simply reversing the SWS abnormalities results in clinical improvement of schizophrenia symptoms. However, there is clinical utility in understanding sleep architecture changes that occur with antipsychotics. For instance, quetiapine is an appropriate choice for sleep-onset insomnia, as it reaches peak blood levels quickly, has a relatively short half-life compared with the other atypical antipsychotics, and significantly shortens sleep latency. Other atypical antipsychotics including olanzapine, risperidone, or clozapine may take up to 1 week for blood levels to peak. 30 Conversely, ziprasidone, olanzapine, or risperidone may be more suitable for sleep maintenance insomnia, owing to their relatively powerful potential to increase SWS; however, daytime sedation can be a side effect. 30
Sleep in Anxiety Disorders
Patients with anxiety disorders, including GAD, PTSD, and panic disorder, often have disturbed sleep. Insomnia is the most common sleep complaint in these disorders. A large cross-sectional study by Ohayon and Roth 39 showed 61% of panic disorder patients and 44% of patients with GAD had insomnia. Insomnia can have several etiologies, including RLS, or an underlying common neurochemical abnormality.
RLS and Anxiety Disorders
RLS is often described as a creepy-crawly or tingling sensation in the lower limbs associated with a strong desire to move, usually worsened by rest and worse in the evenings. 40 Because symptoms frequently occur in late evening, they often cause initial insomnia. RLS is strongly related to PLMD, in which the legs move periodically in the night, usually at 20to 40-second intervals, causing fragmented sleep and middle insomnia. CNS dopamine deficiency is strongly implicated in RLS and PLMD. 41 RLS prevalence estimates indicate 5% to 10% of the population may be affected. 42 Several recent studies highlight a strong preponderance of anxiety disorders in RLS patients, especially panic disorder. 43 The relation may lie in a common dopaminergic abnormality. 43 Antidepressant use is also linked to RLS, including the tricyclics and SSRIs, 44 venlafaxine, 45 and, particularly, mirtazapine. 44 Recent studies suggest an average 5% to 10% increase in incidence of RLS symptoms with SSRI or SNRI antidepressant use, but up to a 30% increase with mirtazapine and no increase with reboxetine use. 44 Although SSRIs and SNRIs may exacerbate RLS, bupropion has been suggested to be neutral for RLS symptoms and possibly even helpful for RLS because of its dopaminergic activity. 46 As untreated RLS is associated with insomnia 47 and poor quality of life, 48 it behooves psychiatrists to recognize this disorder. Many patients with anxiety disorders may have unrecognized RLS. If RLS symptoms occur more than 3 times per week, treatment with a dopamine agonist such as pramipexole or ropinirole 2 hours before bedtime 49 can be beneficial.
GAD and Sleep
GAD is commonly associated with insomnia. Although GAD has a high comorbidity with MDD, polysomnography studies of these patients do not consistently demonstrate the reduction in REM latency seen in MDD. 50 These studies also showed that GAD patients have less SWS and more awakenings than control subjects. 51 Daytime vigilance and attention remain stable despite SWS deprivation and fragmented sleep, but fine motor control and reaction time are diminished, suggesting some deficits from sleep disturbances. 52 
PTSD and Sleep
Studies evaluating sleep in PTSD have shown frequent arousals, fragmented sleep, and increased motor activity. 57 Although reports on sleep architecture changes are inconsistent, a large recent meta-analysis showed PTSD patients have more Stage 1 sleep, less SWS, and higher REM density. 58 The losses in SWS may be mediated by increases in cerebrospinal fluid CRF, which is known to inhibit SWS. 59 CRF dysregulation may be a core feature of PTSD; as a result, CRF receptor antagonists are being developed as therapeutic targets for treatment of PTSD symptoms. 59, 60 REM sleep abnormalities in PTSD have attracted significant attention. Several studies show higher REM density and increased REM latency 61 in these patients. Multiple lines of evidence suggest REM sleep continuity is disrupted in chronic PTSD. 62, 63 Some studies have demonstrated increased muscle tone in REM sleep, further suggesting a dysfunction of REM sleep mechanisms, as REM sleep normally has skeletal muscle atonia. 57, 64 PLMs also occur frequently in PTSD. 57 Dream enactment behaviour has also been evaluated in patients with PTSD, 64,65 though surprisingly few studies have evaluated this comorbidity, given how often parasomnia behaviours occur, including yelling, shouting, and kicking.
Nightmares and PTSD
Nightmares occur in up to 96% of PTSD patients, 66 predominantly emerging from REM sleep. 63 Mellman 51 has observed that in patients exposed to trauma, those who develop PTSD describe dream content that is "highly replicative" p 1052 of the trauma; whereas those who do not develop PTSD describe dreams with a significant fear component but that are not replicative of the traumatic events. Mellman theorizes that these replicative dreams in PTSD represent a "failure of adaptive emotional memory that is a normal functioning of REM sleep and dreaming." 51, p 1052 This theory is consistent with Walker's "sleep to forget hypothesis" 7, p 190 (discussed earlier), as PTSD is envisioned as a failure of the normal function of REM sleep to remove the emotional content of a memory, leading some to speculate that PTSD symptoms may represent a form of sleep disorder, 67 in contrast to the traditional view that sleep disturbances are a symptom of PTSD.
Several nonpharmacologic measures have been shown to be beneficial for nightmares, including imagery rehearsal therapy and CBT, either alone or in combination. 68 Eye movement desensitization and reprocessing may also help with sleep efficiency in PTSD. 69 Another nonpharmacologic intervention for PTSD is CPAP. Some studies have demonstrated frequencies of OSA in PTSD patients of more than 90%, 70 while another study of community patients with PTSD showed no increase in OSA. 62 Treatment of underlying OSA in PTSD patients may significantly improve nightmares and insomnia symptoms. 71 Patients with PTSD and OSA may not report the typical sleepiness reported by classic OSA patients, as this may be masked by heightened anxiety; instead, they may report fatigue or tiredness. Krakow et al 72 demonstrated that these patients report nocturia, morning headaches, and dry mouth, which may be better indicators of comorbid OSA in this population. For excellent reviews of sleep abnormalities in PTSD, see Spoormaker and Montgomery 67 and Germain et al. 73 The heightened arousal and disturbing dreams in PTSD likely originate from an overactive noradrenergic system, with involvement of the limbic system including the amygdala and medial prefrontal cortex. 73 Prazosin, an alpha-1 adrenergic antagonist, has significant nightmare attenuation properties. This agent diminishes noradrenergic activity of the locus coeruleus, thereby decreasing nightmare frequency and intensity. 74, 75 Studies used between 1 and 20 mg/day, with a mean effective dosage of 2 to 13 mg/day. 75 The 5-HT 2A receptors also play an important role in nightmare experiences and sleep disturbances in PTSD. Other medications that have demonstrated efficacy for sleep in PTSD include 5-HT 2 antagonists, many with antiadrenergic activity, including trazodone, 76 mirtazapine, 77 olanzapine, 78 risperidone, 79 quetiapine, 80 aripiprazole, 81 as well as the anticonvulsants topiramate 82 and gabapentin. 83 The latter 2 agents may reduce kindlinghyperreactivity of the limbic system. Other recently studied medications with demonstrated sleep benefits in PTSD include nabilone 84 and dehydroepiandrosterone-sulphate. 85 For further details regarding use of these medications, and anecdotal reports of other medications with some demonstrated benefits in sleep parameters for patients with PTSD, see the review by Berger et al. 86 Among the SSRIs, only fluvoxamine 87 has demonstrated improvement in sleep parameters, although SSRIs are still first-line medications for other PTSD symptoms. 86 While benzodiazepines are frequently used, there is sparse literature on their efficacy for sleep in PTSD, with only temazepam demonstrating improvements. 88 Although this paucity of literature has led several investigators to argue against benzodiazepine use in this population, 75, 86 one exception may be when a parasomnia is observed, as clonazepam is highly effective for parasomnias such as sleepwalking 89 and RBD. 89
Sleep and Cognitive Disorders

Normal Sleep Changes in the Elderly
Aging is associated with several changes in sleep architecture.
Large studies indicate that percentages of REM sleep and SWS decrease with age. 90 However, there is consensus that the need for sleep does not change with aging, but the ability to sleep diminishes. 91 The consequences of poor-quality sleep include depression, 92 cognitive dysfunction, 93 poorer quality of life, and increased mortality. 94 Prevalence estimates of sleep complaints in the elderly approach 30% to 50%, 95 making sleep important to address in this population.
Insomnia in the Elderly
Insomnia is the most common sleep difficulty reported in elderly adults, especially elderly women. 96 The prevalence of insomnia increases sharply with the number of medical and psychiatric conditions present, the most common being depression, chronic pain, cancer, chronic obstructive pulmonary disease, and cardiovascular disease. In an extensive review of 6800 elderly patients with insomnia, only 7% of those with incident insomnia did not have one of these conditions, leading the authors to conclude that medical conditions associated with aging lead to insomnia, rather than aging itself. 97 Many medications also have insomnia as a side effect.
Circadian Rhythm Disturbances in the Elderly
The sleep-wake cycle is controlled by the suprachiasmatic nucleus, located in the anterior hypothalamus. Together with external time cues (zeitgebers), particularly exogenous light and endogenous melatonin, the suprachiasmatic nucleus entrains the body's circadian rhythms, including the sleep-wake cycle. This system becomes less robust with age, and more prone to phase advancing. Therefore, the elderly may have a tendency to retire early and arise early. Consequently, 2 patterns may emerge that exacerbate insomnia. 98 Some elderly may stay awake longer, to more socially accepted norms but then wake up early in the morning unable to return to sleep because their bodily rhythm is entrained to an early morning rising. Alternatively, the elderly can feel more fatigued earlier in the day and take daytime naps, causing initial and middle insomnia because of less nocturnal sleep debt.
Sleep Disorders in the Elderly
Obstructive Sleep Apnea-Hypopnea Syndrome. OSA is characterized by repeated pharyngeal obstructions resulting in airflow cessation (apnea) or reduction (hypopnea) during sleep; these lead to sleep deprivation, fragmentation, and hypoxemia. The AHI and Respiratory Disturbance Index (commonly referred to by its acronym, RDI) are 2 measures used to quantify OSA severity. These indices measure the frequencies of sleep-disordered breathing events per hour of sleep, with higher values indicating more severe disturbances. CPAP is usually the optimal treatment for OSA, but surgery (uvulopalatopharyngoplasty) or an oral appliance can be considered for milder cases, although these are used infrequently in OSA in the elderly.
Among adults aged 30 to 60 years, the prevalence of OSA, defined as an AHI of greater than 5, is 9% for women and 24% for men. 99 The prevalence of OSA-HS, defined as an AHI of greater than 5 and daytime hypersomnolence, is 2% for women and 4% for men. 99 For people aged 61 years and older, prevalence rates of OSA may rise sharply. The Sleep Heart Health Study, 100 one of the largest studies evaluating OSA in the elderly, showed stable prevalence rates across age groups from 60 to 98 years, with 51% to 66% having an AHI of more than 5. Several medical conditions predispose the elderly to developing OSA, including stroke, diabetes (with autonomic neuropathy possibly altering ventilatory control mechanisms), renal failure (possibly owing to excess fluid accumulation), hypothyroidism, obesity, and heart disease. However, other studies show an increased risk of OSA in geriatric patients in the absence of these conditions (reviewed by Norman and Loredo 101 ). Multiple mechanisms have been suggested to explain this increased vulnerability to developing OSA, including decreased pharyngeal dilator activity, and excess pharyngeal fat deposits (reviewed by Norman and Loredo 101 ). Additionally, postmenopausal women not on hormone replacement therapy may lose the protective effect of estrogen on the upper airway. 101 Further, patients with dementias may have progressive deterioration of brain stem structures involved in maintaining airway patency and consequently are at higher risk of developing OSA. 102 Although snoring and daytime sleepiness are common OSA symptoms in elderly patients, other symptoms include insomnia, nocturia, irritability, morning headaches, depression, and cognitive impairment. 101 Clinicians may overlook these clues, ascribing these symptoms to aging or medical issues. 103 Patients with more severe OSA perform worse on dementia rating scales, suggesting a correlation between dementia and OSA severity. 104 Other studies highlight the strong association between OSA and increased risk of cardiovascular disease including heart disease, and hypertension in the elderly population. 101, 105 As there are significant consequences for OSA in the geriatric population, the psychiatrist should maintain a high index of suspicion, as OSA is common and often undiagnosed. Referral should be considered if there are symptoms suggestive of OSA with comorbid nocturia, cardiovascular disease, hypertension, or cognitive dysfunction. 106 CPAP is the treatment of choice, and has been shown to improve cognitive functioning. 104 Although CPAP compliance may be challenging, contrary to what clinicians may believe, patients with dementia can adapt to CPAP use with proper assistance. A study by Ayalon et al 107 showed that neither age, severity of dementia, nor severity of OSA correlated with poor CPAP adherence; only comorbid depression predicted poorer compliance.
RLS and PLMD in the Elderly
The prevalence of RLS and PLMD rises sharply with age, 108 with women twice as likely to be affected as men. RLS exacerbates initial insomnia, as symptoms usually occur before sleep onset. PLMD may exacerbate middle insomnia because nocturnal leg movements can fragment sleep. Both respond to dopaminergic therapy, including ropinirole or pramipexole, considered first-line pharmacologic recommendations. 49 These agents may be problematic for patients with psychotic symptoms and (or) impulse control difficulties, including pathological gambling and hypersexuality. 109 Another option is gabapentin. 49 Benzodiazepines and opioids are considered third-and fourth-line options. 49
RBD in the Elderly
In RBD, the normal skeletal muscle atonia of REM sleep is intermittently absent, resulting in complex motor behaviours during REM sleep; dream content is then enacted, often involving themes of aggression or self-defence. Almost 90% of affected patients are male, often presenting in their 60s. 110 These patients are at high risk for developing alpha synucleinopathies, including Parkinson disease, Lewy Body Dementia, and Multisystem Atrophy. 111 Recent research suggests RBD patients have a 20% risk of developing Parkinson disease or dementia within 5 years, and a 40% risk in 10 years, 112, 113 suggesting RBD is an early clinical marker of these disorders. Several case reports have identified medications that exacerbate RBD, including tricyclic antidepressants, 64 monoamine oxidase inhibitors, 114 SSRIs, 115 mirtazapine, 116 and venlafaxine. 115 RBD responds to clonazepam (0.5 to 2.0 mg at bedtime) in 80% of patients. 117 However, clonazepam can increase fall risk and worsen OSA; in these patients, melatonin may be beneficial. 118
Sleep in Dementia
Sleep is frequently disturbed in patients with dementia. Often, they are institutionalized and consequently have little ambient light exposure. They may also have high exposure to nocturnal noise and medications affecting sleep. 119 Suprachiasmatic nucleus neurons may degenerate more quickly in patients with progressive dementias. 120 Melatonin, a hormone normally produced by the pineal gland to regulate sleep cycles, has been shown to be diminished by up to 80% in elderly patients with dementia. 121 Investigators have examined melatonin use for insomnia in dementia patients, with benefit in some, 122 but not all studies. 123 A synthetic melatonin receptor agonist, ramelteon, has been developed and approved for treatment of insomnia in the United States. 124 For a review on other medications used for insomnia in the elderly population, see Bloom et al. 124 Additionally, the elderly may have insomnia related to pain, medications, depression, or a primary sleep disorder such as OSA, RLS, PLMD, or RBD. Treatment should begin by addressing all the aforementioned disorders. Several studies demonstrated that increasing bright light exposure, minimizing ambient noise, and addressing sleep hygiene are effective at improving sleep quality and consolidating the sleep-wake cycle. 125, 126 CBT, which includes a combination of sleep hygiene, relaxation techniques, stimulus control, and sleep restriction, was more effective at maintaining improvements in insomnia than temazepam at 2-year follow-up. 127
Substance Use and Sleep
Alcohol and Sleep Acute alcohol use results in decreased sleep latency, modest increases in SWS, and a reduction of REM sleep in the first 2 to 4 hours of the night. 128 These properties make alcohol an appealing hypnotic; up to 67% of insomniacs report alcohol as an effective hypnotic. 129 However, during the second half of the night, REM sleep rebounds and is associated with intense dreaming and nightmares, leading to sleep fragmentation and decreased sleep efficiency. 128 These disruptive effects can even be seen 6 hours after happy hour drinking (about 5 PM); that is, when blood alcohol levels are zero. 130 However, the effects of chronic alcohol use are quite different from acute use. Tolerance to alcohol's sleep-enhancing effects develops within 3 to 9 nights of daily alcohol use. 130 Chronic use leads to increased sleep latency and decreased sleep efficiency, SWS, REM sleep, and TST. 128 These disturbances can persist months after alcohol cessation, even up to 2 years, although gradual improvement is generally noted. 130, 131 Sleep disturbances persisting in early recovery from alcohol dependence are associated with higher relapse risk. 132, 133 Benzodiazepines for the treatment of insomnia are avoided because of their abuse potential in abstinent alcoholics. Very little work has been done on evaluating other related pharmacologic agents for insomnia in these patients, such as zopiclone, zolpidem, or zaleplon, because of similar concerns. Medications shown to improve sleep disturbances in this population include trazodone, 134 carbamazepine, 135 acamprosate, 136 and gabapentin. 137 Alcohol use may exacerbate several sleep disorders, including OSA, PLMD, and RLS, as well as parasomnias such as sleepwalking and RBD. OSA and snoring are worsened by alcohol, even after a single drink. 130 PLMD and RLS prevalence increases 2-to 3-fold in patients having 2 or more drinks per day. 130 The exacerbation of parasomnias, such as sleepwalking, may also have distinct forensic implications, 128 including "sexsomnia," 138, p 272 a potentially violent parasomnia where sexual behaviours are enacted in sleep. 138
Opiates and Sleep
Most studies of opioid effects on sleep have examined heroin, morphine, and methadone. Acute opioid administration causes reductions in TST, REM sleep, and SWS. 139 With chronic opioid use, these changes are minimized. In opioid withdrawal, insomnia frequently occurs, with reduced SWS and markedly diminished REM sleep. 140 Maximal REM and SWS suppression occurs 2 to 3 days into abstinence for chronic heroin users, and some suppression persists for 5 to 7 days into abstinence. 141 With protracted abstinence, TST, REM sleep, and SWS subsequently increase (rebound). The time course for changes in sleep architecture have not been studied for each opioid; however, for methadone, REM and SWS rebound occurs 13 to 22 weeks after methadone withdrawal. 139 These sleep changes may explain some behavioural changes seen during this withdrawal phase, including initial irritability, 140 which may be connected to REM and (or) SWS deficits. REM sleep deprivation may be hyperalgesic, 142 leading to speculation that opioids paradoxically reduce the pain threshold by reducing REM sleep, possibly resulting in a vicious cycle of excess opioid requirements. 143 However, pain itself also reduces REM and NREM sleep, and disrupts sleep continuity, thereby making this a complex relation requiring further study.
Several sleep complications occur with chronic opioid use, especially methadone. Chronic opioid use is associated with the development of central sleep apnea occurring as a consequence of chronic suppression of ventilatory drive. This dose-dependent phenomenon has been seen in 30% of patients on stable methadone maintenance. 144 An increase in OSA has also been observed in 39% of patients receiving chronic opioid therapy 145 ; these phenomena may play a role in the sleep disturbances and increased mortality seen in these patients. 146
Cannabinoids and Sleep
Studies on the main active ingredient of marijuana, delta-9 tetrahydrocannabinol, show decreases in sleep latency, 147, 148 making marijuana potentially appealing as a sedative. Both increases and decreases in SWS have been seen with marijuana use. 149 Tolerance to sleep-induction effects of marijuana has been demonstrated in studies of chronic marijuana users. 149 Marijuana's sleep effects can be variable 149 because it contains numerous compounds, some with sedative effects and others with wakefulness-promoting properties such as cannabidiol. 147, 148 Marijuana also decreases REM sleep and REM density. 149 These findings have led investigators to use nabilone, a synthetic cannabinoid, for mitigating PTSD nightmares with some reported success. 84 Cannabis withdrawal has been associated with sleep disturbances, with disturbing dreams most consistently reported. 150 Withdrawal symptoms begin 2 to 3 days after the last cannabis use and generally last up to 2 weeks, although they can persist up to 7 weeks. 149 Sleep onset latency increases, with reduced SWS and increased REM sleep, 149 consistent with the disturbing dreams reported by patients. 150
Summary
Sleep and sleep disorders are intimately tied to psychiatric illness. This is true at both the clinical-behavioural and the neurochemical levels. Most psychiatric medications target receptors involved in the control of sleep. Additionally, it appears that physical sleep disorders are pathoplastic to psychiatric disorders, and need to be suspected by every practising psychiatrist when evaluating the sleep complaints of their parents. Future research may change the way psychiatric disorders are viewed, with a growing understanding of the bidirectional relation between sleep disturbances and psychiatric symptoms. There is an opportunity to develop new treatment strategies for psychiatric disorders based on a broader understanding of sleep physiology and pathophysiology.
